Speciality: Pulmonary Medicine
Description:
A warm welcome to all the medical professionals in this interesting session on Choosing omalizumab in severe allergic asthma: evidence and practices
Omalizumab, an anti-IgE monoclonal antibody, has become a key treatment for patients with severe allergic asthma who remain uncontrolled despite standard therapies. By targeting IgE, a critical player in allergic responses, omalizumab helps reduce exacerbations, improve lung function, and enhance quality of life. Clinical evidence shows that it is particularly effective in patients with elevated serum IgE levels and frequent asthma attacks.
When choosing omalizumab, physicians consider factors like the patient’s IgE levels, asthma severity, and response to previous treatments. Guidelines support its use in patients with allergic asthma not controlled by inhaled corticosteroids and long-acting beta-agonists. Regular monitoring and patient education are essential, as the treatment is typically administered subcutaneously every 2 to 4 weeks, providing a personalized approach for managing severe asthma.
Therefore, get an overall knowledge of choosing omalizumab in severe allergic asthma: evidence and practices. Listen to the webinar, grab the shared knowledge, and follow Hidoc for more such interesting webinar sessions.
See More Webinars @ Hidoc Webinars
1.
Adult overdose deaths on the rise
2.
What Role Should Genomic Classifier Testing Play in Prostate Cancer?
3.
To automate the biopharmaceutical facilities of Reliance Life Sciences, ABB India has won the contract.
4.
Cancer tumor anatomy influences the benefits of chemotherapy for patients with early-stage breast cancer.
5.
New study links air pollution with higher rates of head and neck cancer
1.
Liquid Biopsy in Oncology: Innovations in Cancer Detection, Monitoring, and Clinical Use
2.
Essential Oncology Tools: Risk Assessment, Telehealth, AI, and Monitoring
3.
The Importance of Maintaining Normal Calcium Levels in Your Body
4.
The Truth About Marijuana and Its Effect on Mental Health
5.
Mastering Modern Oncology: Accreditation, Education, and Research Trends for 2025
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Efficient Management of First line ALK-rearranged NSCLC - Part II
2.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- The Conclusion
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC
4.
Exploring the Hospitalization Burden in Refractory and Relapsed ALL
5.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation